Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARDBiotechnology
+$0.09 today
- Market cap
- $86.45M
- Beta
- 4.47
- P/E (TTM)
- -1.2
- EPS (TTM)
- -$3.20
Volume 1.32M
Average 0.18M
AARD Total Current Liabilities
All obligations due within one year.
Aardvark Therapeutics, Inc. Common StockNASDAQ: AARD
Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total current liabilities rises 94.2% from a year ago
Total current liabilities stood at $11.6M at the end of Q1 FY2026, up 94.2% from a year earlier and up 10.0% from the prior quarter. Over 3 fiscal years it compounded at +160.7% a year.
Context
- Total current liabilities amounted to 11.8% of total assets at the end of Q1 FY2026, up 8.0 pp from a year earlier.
- Total current liabilities increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total current liabilities keeps rising in the next quarterly balance sheet after a +94.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 10.55M USD
- Year-over-year change
- +114.1%
- 3-year CAGR
- +160.7%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 10.55M | +114.1% |
| FY2024 | 2024-12-31 | 4.93M | +256.5% |
| FY2023 | 2023-12-31 | 1.38M | +132.3% |
| FY2022 | 2022-12-31 | 595K | — |
Total Current Liabilities vs competitors
How AARD compares with its peers on the latest reported figures
- AARD's Mar 2026 total current liabilities of $11.6M is the 8th highest of the 11 companies compared; the peer median is $16.66M.
- Its year-over-year change of +94.2% is the 3rd highest of 11, against a peer median of +1.7%.
- Total current liabilities amounts to 11.8% of total assets for AARD, versus a peer median of 12.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $64.4M | -9.7% | +2.7% | 29.0% | |
| Mar 2026 | $46.44M | +1.1% | +17.6% | 14.8% | |
| Mar 2026 | $35M | -24.9% | +44.1% | 14.9% | |
| Mar 2026 | $19.67M | -31.0% | -3.3% | 13.2% | |
| Mar 2026 | $16.78M | +18.6% | -14.0% | 12.4% | |
| Mar 2026 | $16.53M | +14.6% | -12.6% | 25.7% | |
ZURAZura Bio Limited | Mar 2026 | $11.75M | -44.3% | -5.7% | 5.1% |
| Mar 2026 | $11.6M | +94.2% | +160.7% | 11.8% | |
| Mar 2026 | $11.6M | +106.6% | -16.4% | 11.6% | |
| Mar 2026 | $8.34M | +2.3% | +5.4% | 4.7% | |
EPRXEupraxia Pharmaceuticals Inc. | Mar 2026 | $7.39M | +235.8% | +10.8% | 5.1% |
| Peer median (excluding AARD) | $16.66M | +1.7% | -0.3% | 12.8% | |
Competitors are the stored peer set for AARD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARD
Intrinsic Alpha fair value
Locked
Current Price
$3.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.